Sign In
Buy CLLS
$3.09
-0.290 (-8.58%)
At Close: Jun 03, 2026
Cellectis annonce ses résultats financiers pour le premier trimestre 2022
08:42pm, Thursday, 05'th May 2022 GlobeNewswire Inc.
NEW YORK, 05 mai 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de génom
Cellectis to Report First Quarter 2022 Financial Results
08:40pm, Thursday, 05'th May 2022 GlobeNewswire Inc.
NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to
Calyxt, Inc., Cellectis’ Majority-Owned Subsidiary, Reports Its First Quarter 2022 Financial Results
08:14pm, Thursday, 05'th May 2022 GlobeNewswire Inc.
NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- Cellectis S.A. (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-s
Cellectis to Report First Quarter 2022 Financial Results
04:40pm, Thursday, 05'th May 2022
NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to d
Cellectis reçoit une note convertible de 20 millions de dollars dans le cadre de l’accord de collaboration avec son partenaire Cytovia Therapeutics
06:44am, Wednesday, 27'th Apr 2022 GlobeNewswire Inc.
Cellectis Receives $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics
06:44am, Wednesday, 27'th Apr 2022 GlobeNewswire Inc.
NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platfor
NEW YORK, April 08, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform
NEW YORK, 08 avr. 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de géno
Iovance (IOVA) Stock Rallies 33% in a Month: Here's Why
07:17pm, Friday, 08'th Apr 2022 Zacks Investment Research
Iovance (IOVA) to complete the FDA filing for its lead candidate in melanoma by August. It will start a clinical study for its first TALEN-edited TIL therapy for two advanced cancer indications later
Monthly information on share capital and company voting rights
08:30pm, Thursday, 07'th Apr 2022 GlobeNewswire Inc.
(Article 223-16 of General Regulation of the French financial markets authority) (Article 223-16 of General Regulation of the French financial markets authority)
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
08:30pm, Thursday, 07'th Apr 2022 GlobeNewswire Inc.
(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers)
Allogene: Speculative CAR T Biotech With Big Potential In Oncology
10:54pm, Friday, 01'st Apr 2022
Allogene: Speculative CAR T Biotech With Big Potential In Oncology
Iovance Receives FDA Allowance For IOV-4001 Study In Two Advanced Cancers
01:21pm, Wednesday, 16'th Mar 2022 Benzinga
The FDA has signed off Iovance Biotherapeutics Inc''s (NASDAQ: IOVA ) Investigational New Drug Application (IND) first genetically modified TIL therapy, IOV-4001, for unresectable or metastatic melanoma and stage III or IV non-small-cell lung cancer (NSCLC). IOV-4001 leverages the gene-editing TALEN technology licensed from Cellectis SA (NASDAQ: Full story available on Benzinga.com
Clinical Study Expected to Begin in 2022 to Investigate the Safety and Efficacy of IOV-4001 to Deliver TIL and PD-1 Inhibition within a Single Cancer Therapy First Genetically Modified Iovance TIL Therapy Leverages TALEN® technology Licensed from Cellectis to Inactivate PD-1 Expression SAN CARLOS, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA ), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has allowed an Investigational New Drug Application (IND) to proceed for its first genetically modified TIL therapy, IOV-4001, for the treatment of unresectable or metastatic melanoma and stage III or IV NSCLC. IOV-4001 leverages the gene editing TALEN® technology licensed from Cellectis (NASDAQ: CLLS ), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop potentially life-saving cell and gene therapies, to inactivate the gene coding for the PD-1 protein.
Cellectis S.A. (NASDAQ: CLLS) Up 4.76%: This Is What Analysts Now Expect
04:30pm, Saturday, 12'th Mar 2022 Stocks Register
Cellectis S.A. (NASDAQ:CLLS) shares, rose in value on Friday, 03/11/22, with the stock price up by 4.76% to the previous day’s close as strong demand from buyers drove the stock to $4.40. Actively observing the price movement in the last trading, the stock closed the session at $4.20, falling within a range of $4.34 and … Cellectis S.A. (NASDAQ: CLLS) Up 4.76%: This Is What Analysts Now Expect Read More »
